| News

Hemex attracts Swiss investors

11.02.2021

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The biotech incubator will use the funds to accelerate its global expansion.

Hemex, a Basel Area-based venture capitalist and incubator for biotech startups, has reported raising “a substantial amount” in an oversubscribed Series C financing round. According to a press release, the capital contribution was raised exclusively from a group of Swiss private investors.

Now, Hemex plans to use this money to hire “world-class talent” and accelerate its global expansion. The company wants to “invest in carefully selected startups” and deliver on its promise of “changing the future of healthcare”.

“We anticipate another year of strong growth for healthcare, both domestically and on a global level,” said Hemex CEO Pascal Winnen in the press release. “This vote of confidence for our business model from a group of successful entrepreneurs confirms that Hemex is on the right track for substantial future success.”

Hemex’s partners include the investment and innovation promotion agency Basel Area Business & Innovation and its DayOne Accelerator. Its portfolio includes Opterion Health AG, which announced at the end of January that it would be moving from the canton of Obwalden to the co-working space The 5th Floor in Muttenz. Basel Area Business & Innovation is providing support for the relocation.

In addition, Hemex has invested in Scailyte, a company based at the Novartis Campus of the Switzerland Innovation Park Basel Area. Support has also been provided to Resistell based in Muttenz, which claims to have made the world’s fastest antibiogram, and Basel cancer diagnostics expert Artidis.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Hemex attracts Swiss investors
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Hemex attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The...

Read More
Rhizen drug secures approval in the USA
Basel Area Business & Innovation, Innovation, Invest

Rhizen drug secures approval in the USA

The United States Food and Drug Administration has granted accelerated approval for the drug Umbralisib. Basel biotech Rhizen has discovered...

Read More
Novaremed secures US$50 million
Basel Area Business & Innovation, Innovation, Invest

Novaremed secures US$50 million

Basel biotech Novaremed is receiving US$50 million through an agreement with an investment group. Novaremed will use this financing to...

Read More
Axtria driving growth from Basel
Basel Area Business & Innovation, Innovation, Invest

Axtria driving growth from Basel

The US firm Axtria has established a new office in Basel. The company offers services for the life sciences industry...

Read More
Technologiepark Basel celebrates its role as a driver of innovation
Basel Area Business & Innovation, Innovation, Invest

Technologiepark Basel celebrates its role as a driver of innovation

The Technologiepark Basel will be ten years old in 2021. Over the past decade, it has supported many startups and...

Read More
Basel Area has ever more to offer investors
Basel Area Business & Innovation, Innovation, Invest

Basel Area has ever more to offer investors

The canton of Basel-Stadt has displayed the most striking performance in the Swiss Venture Capital Report. Last year, more than...

Read More
1 2 3 7

Do you have a question? We'd like to hear from you.